0.873
-0.41 (-31.81%)
| Penutupan Terdahulu | 1.28 |
| Buka | 1.32 |
| Jumlah Dagangan | 369,087 |
| Purata Dagangan (3B) | 82,708 |
| Modal Pasaran | 5,286,514 |
| Harga / Buku (P/B) | 1.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 May 2025 - 19 May 2025 |
| EPS Cair (TTM) | -8.37 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.19% |
| Nisbah Semasa (MRQ) | 1.41 |
| Aliran Tunai Operasi (OCF TTM) | -19.12 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -14.10 M |
| Pulangan Atas Aset (ROA TTM) | -67.48% |
| Pulangan Atas Ekuiti (ROE TTM) | -182.30% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | NuCana plc | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.83 |
|
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.21% |
| % Dimiliki oleh Institusi | 11.72% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Glass Jacobson Investment Advisors Llc | 31 Dec 2024 | 15,000 |
| Allsquare Wealth Management Llc | 31 Dec 2024 | 205 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Mar 2025 | Pengumuman | NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update |
| 20 Mar 2025 | Pengumuman | NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |